October 3, 2025
CORRECTION – Algae-C Acquisition by Rockcliffe Labs
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Algae-C Inc. (“Algae-C”) today issues a correction to its earlier release announcing its…
Pharmaceuticals, Biotechnology and Life Sciences
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Algae-C Inc. (“Algae-C”) today issues a correction to its earlier release announcing its…
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ:…
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing…
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional…
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE…
TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
Conference call and webcast on Monday, September 29, 2025 at 8:00 am EDTBALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE)…
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate…